Trial Profile
Analysis of ABCG2 genotype in Gleevec treated cancer patients to assess the association of a single nucleotide polymorphism (C421A) in ABCG2 and response to treatment.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Imatinib (Primary)
- Indications Cancer
- Focus Pharmacogenomic; Therapeutic Use
- 24 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 24 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 20 May 2009 Additional lead trial investigator (Figg WD) identified as reported by ClinicalTrials.gov (NCT00897000)